



Please Send a Copy of The Patient's Insurance Cards (Front & Back)

PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION	
Name: _____ DOB: _____ Address: _____ City, State, Zip: _____ Phone: _____ Alt. Phone: _____ Email: _____ SS#: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F Weight: _____ (lbs) Ht: _____ Allergies: _____		Prescriber Name: _____ State License: _____ NPI #: _____ DEA: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ Office Contact: _____ Phone: _____	
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)			
Primary Insurance: _____ City, State, Zip: _____ Plan #: _____ Group #: _____ Phone: _____		RX Card (PBM): _____ BIN: _____ PCN: _____ City, State, Zip: _____ Group #: _____ Phone: _____	
CLINICAL INFORMATION			
<input type="checkbox"/> K51.90 Moderate to Severe Ulcerative Colitis <input type="checkbox"/> K50.90 Moderate to Severe Crohn's Disease <input type="checkbox"/> M06.9 Rheumatoid Arthritis <input type="checkbox"/> M45.9 Ankylosing Spondylitis <input type="checkbox"/> L40.52 Psoriatic Arthritis <input type="checkbox"/> L40.0 Plaque Psoriasis <input type="checkbox"/> Other: _____		*If PPD test results are not within 12 months, please perform PPD. Tuberculosis Screening: <input type="checkbox"/> PPD Test Date: ____-____-____ Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive → <input type="checkbox"/> Chest X-Ray Performed Date: ____-____-____ X-Ray Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive → TB treatment Initiated	
Labs: <input type="checkbox"/> CBC q: _____ <input type="checkbox"/> CMP q: _____ <input type="checkbox"/> CRP q: _____ <input type="checkbox"/> ESR q: _____ <input type="checkbox"/> LFTs q: _____ <input type="checkbox"/> X-Ray: _____ <input type="checkbox"/> Other: _____ **Obtain the following labs at prior to start of treatment and at _____ frequency: <input type="checkbox"/> CBC <input type="checkbox"/> CMP <input type="checkbox"/> CRP <input type="checkbox"/> ESR <input type="checkbox"/> LFTs <input type="checkbox"/> X-Ray <input type="checkbox"/> Other: _____			
AVSOLA® ORDERS			
Prescription type: <input type="checkbox"/> New start <input type="checkbox"/> Restart <input type="checkbox"/> Continued therapy Total Doses Received: _____ Date of Last Infusion: _____			
Medication	Directions		Quantity/Refills
Avsola® (infliximab-axxq)	Loading dose: <input type="checkbox"/> 5mg/kg _____ mg IV at week: 0, 2, 6 <input type="checkbox"/> 3mg/kg _____ mg IV at week: 0, 2, 6 <input type="checkbox"/> Other: _____ <input type="checkbox"/> Maintenance dose: (_____ mg/kg) _____ mg IV every _____ weeks		Loading dose: 3 doses. No refills. Maintenance dose: 8-week supply. Refill x 1 year unless noted otherwise. <input type="checkbox"/> _____ week supply Refill x 1 year unless noted otherwise. <input type="checkbox"/> Other: _____
Pre-Medication	Dose/Strength	Directions	
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> 500mg	<input type="checkbox"/> Take 1-2 tablets PO prior to infusion or post-infusion as directed	
<input type="checkbox"/> Diphenhydramine	<input type="checkbox"/> 25mg IV/PO <input type="checkbox"/> 50mg IV/PO	<input type="checkbox"/> Take 1 tablet PO prior to infusion or as directed OR <input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed	
<input type="checkbox"/> Methylprednisolone	<input type="checkbox"/> 40mg <input type="checkbox"/> 100mg <input type="checkbox"/> 125mg	<input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed <input type="checkbox"/> Other: Inject 100mg IV 30 minutes prior to infusion	
<input type="checkbox"/> _____	_____	_____	
ANAPHYLACTIC REACTION (AR):			
<input type="checkbox"/> EpiPen® Auto-injector 0.3 mg (1:1000) Inject IM -or- SubQ to patients who weigh ≥ 66 lbs (≥ 30 kg); may repeat in 3-5 mins x 1 if necessary <input type="checkbox"/> EpiPen Jr® Auto-injector 0.15mg (1:2000) Inject IM -or- SubQ to patients who weigh 33 - 66 lbs (15-30 kg); may repeat in 3-5 mins x 1 if necessary			

Important Information: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

**Please Fax Completed Form To: 888-898-9113****Please Send a Copy of The Patient's Insurance Cards (Front & Back)**

- ☐ Diphenhydramine 50mg (1mL) - Administer 50 mg VIA slow IVP, administer IM if no IV access; may repeat x 1 after 10 mins, if necessary
- ☐ Methylprednisolone 40mg - administer 40 mg IVP -or- IM if no IV access
- ☐ Sodium Chloride 0.9% 500 mL infuse IV at a rate of up to 999 mL/hr
- ☐ Other: _____

SIGNATURE

We hereby authorize Valustar to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral

X _____

Prescriber Signature

Date: _____

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

Important Information: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.